Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NBSE

NeuBase Therapeutics Inc

Dec 01 • 04:00PM ET

0.9100

Dollar change -0.0764
Percentage change -7.75	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.76	Insider Own	29.80%	Shs Outstand	3.73M	Perf Week	34.66%
Market Cap	3.39M	Forward P/E	-	EPS next Y	-	Insider Trans	-19.84%	Shs Float	2.62M	Perf Month	40.00%
Income	-16.99M	PEG	-	EPS next Q	-	Inst Own	9.31%	Short Float / Ratio	0.47% / 0.01	Perf Quarter	-2.97%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-33.74%	Short Interest	0.01M	Perf Half Y	-74.68%
Book/sh	2.45	P/B	0.37	EPS next Y	-	ROA	-57.98%	Target Price	200.00	Perf Year	-81.02%
Cash/sh	3.37	P/C	0.27	EPS next 5Y	4.00%	ROE	-86.15%	52W Range	0.60 - 8.20	Perf YTD	-76.08%
Dividend	-	P/FCF	-	EPS past 5Y	37.15%	ROI	-121.63%	52W High	-88.90%	Beta	1.23
Dividend %	-	Quick Ratio	2.87	Sales past 5Y	0.00%	Gross Margin	-	52W Low	51.67%	ATR	0.12
Employees	37	Current Ratio	2.87	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	63.22	Volatility	36.01% 14.96%
Optionable	No	Debt/Eq	0.58	EPS Q/Q	85.72%	Profit Margin	-	Rel Volume	0.62	Prev Close	0.99
Shortable	Yes	LT Debt/Eq	0.53	Earnings	-	Payout	-	Avg Volume	2.43M	Price	0.91
Recom	2.33	SMA20	31.59%	SMA50	24.10%	SMA200	-59.18%	Volume	1,509,803	Change	-7.75%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-21	Reiterated	H.C. Wainwright	Buy	$15 → $18
Jun-16-20	Initiated	RBC Capital Mkts	Outperform	$16
Feb-07-20	Initiated	Guggenheim	Buy
Feb-06-20	Initiated	Guggenheim	Buy
Nov-21-19	Initiated	Oppenheimer	Outperform	$14
Sep-24-19	Initiated	BTIG Research	Buy	$15

Nov-27-23 09:00AM	Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance (GlobeNewswire)
Sep-08-23 07:00AM	NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder (GlobeNewswire) -16.04%
Sep-06-23 10:00AM	SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE (PR Newswire) +106.96%
Aug-03-23 07:00AM	NeuBase Therapeutics to Explore Strategic Alternatives (GlobeNewswire) -20.49%
Jun-30-23 04:05PM	NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:30AM	Loading…
Jun-29-23 08:30AM	NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors are Non-Immunogenic, Opening the Door to Redosing (GlobeNewswire) -12.76%
Jun-28-23 02:17PM	NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -7.11%
Jun-14-23 08:30AM	NeuBase Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -16.67%
May-24-23 08:00AM	NeuBase to Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-22-23 07:00AM	NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors (GlobeNewswire) +8.99%
May-16-23 04:01PM	NeuBase Announces Formation of Gene Editing Advisory Board (GlobeNewswire)
May-11-23 04:15PM	NeuBase Reports Business Update and Financial Results for the First Quarter of 2023 (GlobeNewswire) +8.48%
May-02-23 05:00PM	NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting (GlobeNewswire)
Feb-14-23 04:10PM	NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023 (GlobeNewswire) -8.08%
Dec-29-22 05:53PM	NeuBase Therapeutics selling stake in company to New York investment firm Alumni Capital (American City Business Journals)
08:00AM	Loading…
Dec-21-22 08:00AM	NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022 (GlobeNewswire) +5.37%
Oct-21-22 08:00AM	NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company (GlobeNewswire)
Oct-14-22 04:05PM	NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing (GlobeNewswire) -9.73%
Sep-22-22 04:05PM	NeuBase to Participate at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire) -11.49%
Aug-11-22 08:00AM	NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022 (GlobeNewswire)
Aug-08-22 09:57AM	We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-29-22 08:01AM	NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO (GlobeNewswire) +8.69%
Jun-01-22 07:00AM	NeuBase to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-17-22 07:00AM	NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution (GlobeNewswire) +7.29%
May-12-22 05:00PM	NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022 (GlobeNewswire)
10:53AM	Insiders who bought in the last 12 months lose an additional US$65k as NeuBase Therapeutics, Inc. (NASDAQ:NBSE) drops to US$29m (Simply Wall St.)
May-02-22 04:30PM	NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting (GlobeNewswire)
Mar-13-22 07:00PM	NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal (GlobeNewswire)
Mar-07-22 08:00AM	NeuBase to Present at Oppenheimers 32nd Annual Healthcare Conference (GlobeNewswire) -10.32%
Feb-28-22 08:00AM	NeuBase Therapeutics to Present New Preclinical Data for Myotonic Dystrophy Type 1 Program at the 2022 MDA Clinical & Scientific Conference (GlobeNewswire)
07:00PM	Loading…
Feb-10-22 07:00PM	NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022 (GlobeNewswire) -12.08%
Feb-01-22 10:44AM	Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Invest In Growth? (Simply Wall St.) +13.16%
Jan-11-22 11:34AM	NeuBase Therapeutics hires new chief financial officer (American City Business Journals)
Jan-10-22 04:02PM	NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer (GlobeNewswire)
Jan-05-22 04:02PM	NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors (GlobeNewswire) -10.34%
Dec-23-21 04:01PM	NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021 (GlobeNewswire) +5.52%
Nov-03-21 04:05PM	NeuBase to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-01-21 01:12PM	Quite a few insiders invested in NeuBase Therapeutics, Inc. (NASDAQ:NBSE) last year which is positive news for shareholders (Simply Wall St.)
Oct-05-21 08:00AM	VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States (GlobeNewswire)
Sep-28-21 04:05PM	NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-21-21 04:54PM	Pittsburgh-based biotech company on a growth path (American City Business Journals)
Sep-15-21 04:05PM	NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire)
Sep-14-21 08:00AM	NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer (GlobeNewswire)
Sep-01-21 04:05PM	NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-31-21 08:45AM	What Type Of Shareholders Make Up NeuBase Therapeutics, Inc.'s (NASDAQ:NBSE) Share Registry? (Simply Wall St.) +8.72%
Aug-12-21 04:01PM	NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights (GlobeNewswire)
Jun-30-21 05:07AM	We're Hopeful That NeuBase Therapeutics (NASDAQ:NBSE) Will Use Its Cash Wisely (Simply Wall St.)
Jun-08-21 12:30PM	NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth (GlobeNewswire)
Jun-02-21 09:00AM	NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8th (GlobeNewswire)
May-25-21 08:00AM	NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer (GlobeNewswire)
May-20-21 08:00AM	NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer (GlobeNewswire)
May-14-21 12:31PM	NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021 (GlobeNewswire) +9.48%
May-13-21 04:05PM	NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021 (GlobeNewswire)
May-12-21 09:00AM	NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors (GlobeNewswire)
Apr-28-21 04:27AM	Insider Buying: The NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Independent Director Just Bought 120% More Shares (Simply Wall St.) +9.68%
Apr-27-21 08:00AM	NeuBase Therapeutics to Present at the B. Riley Securities Virtual Neuroscience Conference (GlobeNewswire)
Apr-26-21 04:01PM	NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Apr-22-21 09:07AM	NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock (GlobeNewswire) -5.00%
Apr-21-21 04:01PM	NeuBase Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Apr-14-21 07:00AM	Coya Therapeutics Announces the Appointment of Hideki Garren, M.D., Ph.D., and Dov Goldstein, M.D., to Its Board of Directors (GlobeNewswire)
Apr-08-21 08:00AM	NeuBase Therapeutics to Host a Virtual R&D Day on June 8th to Provide Updates on the Drug Development Pipeline Targeting Genetic Diseases (GlobeNewswire)
Mar-19-21 05:33AM	Here's What NeuBase Therapeutics, Inc.'s (NASDAQ:NBSE) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Mar-16-21 08:00AM	NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference (GlobeNewswire) -8.07%
Mar-09-21 07:00AM	NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021 (GlobeNewswire)
Feb-11-21 04:01PM	NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021 (GlobeNewswire)
Jan-28-21 08:00AM	NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics (GlobeNewswire)
Jan-22-21 12:14AM	Is Neubase Therapeutics (NBSE) Stock a Buy For 2021? (Insider Monkey) +16.53%
Jan-11-21 06:00AM	NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference (GlobeNewswire)
Dec-23-20 04:05PM	NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020 (GlobeNewswire)
Dec-18-20 11:35AM	NeuBase Therapeutics' CEO, Dietrich A. Stephan, Ph.D., to Present "Accelerating the Genetic Revolution with a New Class of Synthetic Medicines" at Tribe Public's Event on December 22, 2020 (ACCESSWIRE)
Dec-16-20 06:30AM	NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire) +12.67%
Dec-02-20 06:23PM	Here is What Hedge Funds Think About NeuBase Therapeutics, Inc. (NBSE) (Insider Monkey) +7.62%
08:00AM	NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer (GlobeNewswire)
Nov-23-20 08:00AM	NeuBase Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-18-20 01:46AM	Did NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Insiders Buy Up More Shares? (Simply Wall St.)
Nov-17-20 08:00AM	NeuBase Therapeutics Announces Addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to Scientific Advisory Board (GlobeNewswire)
Nov-10-20 08:00AM	NeuBase Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 (GlobeNewswire)
Oct-26-20 08:15AM	NeuBase Therapeutics' CEO, Dietrich A. Stephan, Ph.D., to Present "Manufacturing Heat-Seeking Missiles Against Misbehaving Genes" at Tribe Public's Event on October 28, 2020 (ACCESSWIRE)
Oct-20-20 10:09AM	Oppenheimer: These 2 Stocks Could Double, If Not More (TipRanks) +7.66%
Oct-13-20 08:00AM	NeuBase Therapeutics Announces Addition of Peter Nielsen, Ph.D., Inventor of Peptide Nucleic Acid Technology, to Scientific Advisory Board (GlobeNewswire) +8.70%
Sep-28-20 08:00AM	NeuBase Therapeutics to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5th (GlobeNewswire)
Sep-17-20 08:30AM	NeuBase Therapeutics to Present at the Myotonic Dystrophy Foundation 2020 Virtual Conference (GlobeNewswire)
Sep-08-20 08:00AM	NeuBase Therapeutics to Present at Upcoming Investor Conferences in September 2020 (GlobeNewswire) +6.32%
Aug-31-20 05:00PM	(LD Micro) 360 Companies Set to Present this Week (ACCESSWIRE)
Aug-24-20 05:00PM	NeuBase Therapeutics CEO, Dietrich A. Stephan, Ph.D., to Present at Tribe Publics Presentation and Q&A Webinar Event on August 26, 2020 (ACCESSWIRE)
Aug-20-20 01:09PM	What Kind Of Investors Own Most Of NeuBase Therapeutics, Inc. (NASDAQ:NBSE)? (Simply Wall St.)
Aug-13-20 04:01PM	NeuBase Therapeutics Reports Financial Results for the Third Fiscal Quarter of 2020 (GlobeNewswire)
Aug-06-20 01:43PM	LD Micro: Announces Preliminary List of Presenters for the LD-500 (ACCESSWIRE)
Jun-10-20 04:20PM	Is NeuBase Therapeutics, Inc. (NBSE) A Good Stock To Buy? (Insider Monkey)
May-15-20 08:48AM	Need To Know: NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Insiders Have Been Buying Shares (Simply Wall St.)
Apr-30-20 04:05PM	NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Apr-28-20 09:44AM	NeuBase Therapeutics Announces Pricing of $31,500,000 Public Offering of Common Stock (GlobeNewswire) -6.98%
Apr-27-20 04:01PM	NeuBase Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +5.69%
Mar-31-20 07:01AM	NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL Platform (GlobeNewswire) +14.29%
Dec-02-19 08:00AM	NeuBase Therapeutics Wins The Scientists Top 10 Innovations of 2019 Award for its Janus Base Technology (GlobeNewswire) +8.00%
Nov-25-19 08:00AM	NeuBase Therapeutics to Present at Upcoming Investor Conferences in December (GlobeNewswire)
Nov-24-19 04:30PM	NeuBase Therapeutics, Inc. (NBSE): Hedge Funds Dropped The Ball? (Insider Monkey)
Nov-12-19 09:16AM	NeuBase Therapeutics to Present at the Stifel 2019 Healthcare Conference (GlobeNewswire)
Oct-17-19 08:00AM	NeuBase Therapeutics Announces Issuance of Foundational Patent Covering the Key Building Blocks of PATrOL Enabled Therapies (GlobeNewswire)
Oct-11-19 08:00AM	NeuBase Therapeutics Announces Appointment of Cancer Biologist and RNA Therapeutics Specialist Steven Dowdy, Ph.D., to Scientific Advisory Board (GlobeNewswire)

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm's therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Symetryx Corp	10% Owner	Sep 14	Sale	1.44	129,108	185,916	153,337	Sep 18 04:32 PM
Symetryx Corp	10% Owner	Sep 11	Sale	1.44	3,376	4,861	472,926	Sep 11 05:08 PM
Symetryx Corp	10% Owner	Sep 08	Sale	1.53	128,847	197,136	476,302	Sep 11 05:08 PM
Symetryx Corp	10% Owner	Sep 07	Sale	1.80	74,852	134,734	605,149	Sep 11 05:08 PM
Symetryx Corp	10% Owner	Sep 01	Buy	0.98	61,076	59,732	680,081	Sep 07 05:19 PM
Stephan Dietrich A	Founder and CEO	Aug 02	Option Exercise	0.02	93,234	2,051	93,234	Aug 04 04:39 PM
Stephan Dietrich A	President and CEO	Feb 13	Option Exercise	0.00	655,000	0	1,471,775	Feb 15 07:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NBSE

NeuBase Therapeutics Inc

Upgrade your FINVIZ experience